Vacuums have come a long way from the cumbersome corded models of decades past, but they’re not exactly…cheap. Thankfully, we ...

Fintel reports that on November 14, 2024, Citigroup initiated coverage of Vertex Pharmaceuticals (NasdaqGS:VRTX) with a Buy ...

Vertex also reported a steady increase in its R&D and SG&A expenses, reflecting its aggressive investment in pipeline ...

Vertex (VERX – Research Report), the Technology sector company, was revisited by a Wall Street analyst today. Analyst Chris Quintero from ...

Vertex (VERX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

The average estimate of six analysts surveyed by Zacks Investment Research was for earnings of 14 cents per share. The company posted revenue of $170.4 million in the period, which also beat Street ...

Vertex raised its FY24 product revenue guidance from $10.65B-$10.85B to $10.8B-$10.9B. “Vertex’s product revenue guidance includes ...

Vertex Pharmaceuticals has a virtual monopoly in treating cystic fibrosis, having created and brought to market a function cure for 90% of the CF population. Their pipeline outside of CF has shown ...

Across the recent three months, 6 analysts have shared their insights on Vertex VERX, expressing a variety of opinions spanning from bullish to bearish. The table below offers a condensed view of ...

Vertex has reported phase 3 data on its near-approval pain drug candidate suzetrigine, shedding light on how the non-opioid painkiller combines with ibuprofen and why the prospect failed to match ...

So when a business like Vertex Pharmaceuticals (NASDAQ: VRTX) releases some new data on a potential blockbuster that could be just a few months away from being approved for sale, it's a big ...

Vertex Pharmaceuticals is in the process of getting a new painkiller approved. It just published some data that suggests the candidate will be quite profitable. But regulators still need to sign ...